Overview

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo, Inc.